Related Experiment Videos
A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies
Saul Merin1, Alexey Obolensky, Marilyn D Farber
1Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. merin@md.huji.ac.il
Purpose:
The aim of this study was to assess the neuroprotective effect of a topical alpha2-agonist in patients with retinal dystrophies.
Methods:
This study was a prospective, placebo-controlled, double-masked, randomized clinical trial. A total of 26 patients with retinal dystrophies were included. One (1) randomly selected eye was treated with brimonidine tartrate 0.2% twice-daily, while the fellow eye received artificial tears. Disease progression parameters tested at 6-8-month intervals throughout the study included Goldmann visual fields, contrast sensitivity, color vision, and fullfield electroretinography.
Results:
Seventeen (17) of the 26 recruited patients completed the study. Except for 1 patient with an 18-month follow-up, all patients were followed up for 24-36 months (mean, 29). At the conclusion of the study, there were no differences detected in visual acuity, color vision, and contrast sensitivity between the treated and control eyes. There was a trend, however, toward a lesser degree of visual field loss in the brimonidine-treated eyes. There was also a delay in the time required to reach a 25% visual field loss in the treated eyes. These differences were more pronounced in a subgroup of patients diagnosed as retinitis pigmentosa and with visual fields of 5 cm2 or more at baseline.
Conclusions:
The findings of this pilot study suggest a trend for slower progression in the eyes of patients with retinal dystrophy when treated with brimonidine, according to one of the parameters that was studied (visual field loss). Further studies that include a larger number of patients and a longer follow-up period are needed to clarify and confirm the potential neuroprotective effect of alpha2-agonists in human retinal dystrophies.
Insights
This pilot study suggests topical brimonidine may slow visual field loss in retinal dystrophy patients. Further research is needed to confirm the neuroprotective effect of alpha2-agonists in these conditions.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Retinal dystrophies are a group of inherited eye diseases causing progressive vision loss.
- Identifying neuroprotective strategies is crucial for managing these debilitating conditions.
Purpose of the Study:
- To evaluate the potential neuroprotective effect of a topical alpha2-agonist, brimonidine tartrate, in patients diagnosed with retinal dystrophies.
- To assess the impact of brimonidine on disease progression parameters.
Main Methods:
- A prospective, placebo-controlled, double-masked, randomized clinical trial involving 26 patients with retinal dystrophies.
- One eye was treated with brimonidine tartrate 0.2% twice daily, while the fellow eye received artificial tears.
- Disease progression was monitored using Goldmann visual fields, contrast sensitivity, color vision, and full-field electroretinography over 24-36 months.
Main Results:
- No significant differences were observed in visual acuity, color vision, or contrast sensitivity between brimonidine-treated and control eyes.
- A trend towards reduced visual field loss and a delayed time to 25% visual field loss was noted in brimonidine-treated eyes.
- These effects were more pronounced in patients with retinitis pigmentosa and baseline visual fields of 5 cm2 or more.
Conclusions:
- This pilot study indicates a potential trend for slower disease progression, specifically in visual field loss, with topical brimonidine treatment in retinal dystrophy patients.
- Larger clinical trials with extended follow-up are necessary to validate the neuroprotective efficacy of alpha2-agonists in human retinal dystrophies.
